OS Therapies Incorporated Cash Flow Conversion Efficiency
OS Therapies Incorporated cash flow conversion efficiency. Based on the latest financial reports, OS Therapies Incorporated (OSTX) has a cash flow conversion efficiency ratio of -1.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.71 Million) by net assets ($4.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OS Therapies Incorporated (2020–2024)
Cash flow conversion efficiency of OS Therapies Incorporated from 2020 to 2024. This chart illustrates how OS Therapies Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OSTX stock price and chart for real-time trading data and today's change.
OS Therapies Incorporated Cash Flow Conversion Ratio Explained
OS Therapies Incorporated cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OS Therapies Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OS Therapies Incorporated ranked by their cash flow conversion efficiency. Also see OS Therapies Incorporated (OSTX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKB Shutters Corporation Bhd
KLSE:7115
|
0.042x |
|
Synergetic Auto Performance Public Company Limited
BK:ASAP
|
1.134x |
|
Entertainment Network (India) Limited
NSE:ENIL
|
-0.015x |
|
JSS Real Estate SOCIMI SA
MC:YJSS
|
0.002x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
Australian Vanadium Ltd
AU:AVL
|
-0.040x |
|
Adaptimmune Therapeutics plc
F:473A
|
0.490x |
Annual Cash Flow Conversion Efficiency for OS Therapies Incorporated (2020–2024)
The table below shows the annual cash flow conversion efficiency of OS Therapies Incorporated from 2020 to 2024. Review OSTX free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $811.49K | $-7.28 Million | -8.974x | -7267.42% |
| 2023-12-31 | $-24.02 Million | $-3.01 Million | 0.125x | -42.04% |
| 2022-12-31 | $-17.56 Million | $-3.79 Million | 0.216x | -43.82% |
| 2021-12-31 | $-11.45 Million | $-4.40 Million | 0.384x | +0.81% |
| 2020-12-31 | $-6.33 Billion | $-2.41 Billion | 0.381x | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more